The use of inhibitors for Raf/MEK/ERK, PI3K/Akt/mTOR, and Jak/STAT signaling in tyrosine kinase receptors (TKR)-based systemic therapy for HCC was recently published [72]. Here, AKT1 is linked to hepatocellular carcinoma.